Navigation Links
Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives
Date:12/5/2007

in which we have successfully achieved several major goals," said Edward Lanphier, president and CEO of Sangamo. "The progress that we have made this year in both clinical and business development activities put us in a very strong position to continue to advance and commercialize our ZFP technology in therapeutics, plant agriculture, laboratory reagents and enhanced cell-lines for pharmaceutical protein manufacturing. We expect 2008 to be another year of significant accomplishments for Sangamo as we achieve a number of major value-creating events."

Mr. Lanphier continued, "We presented positive top-line clinical data from our Phase 1b trial of our lead ZFP Therapeutic(TM), SB-509, an activator of vascular endothelial growth factor (VEGF) for the treatment of diabetic neuropathy (DN). Sangamo is building on this positive data by initiating further clinical trials as we continue our efforts to develop this technology as a novel platform for therapeutic development. This year we also achieved our goal of successfully completing the accrual of subjects to the Phase 2 trial of SB-509 for DN which will give us data in the second half of 2008. In addition to our two Phase 2 clinical trials in DN, we have announced our plans to initiate further Phase 2 studies of SB-509 in stem cell mobilization and amyotrophic lateral sclerosis (ALS) and to initiate two Phase 1 clinical trials in ZFP-mediated gene modification for glioblastoma and HIV/AIDS. We have also advanced and expanded our preclinical pipeline and presented data from several programs at major scientific and medical meetings.

"We also continued to monetize our technology outside of the human therapeutic space. This year we established a major relationship with Sigma-Aldrich Corporation to develop and commercialize ZFP-based laboratory research reagents. We also entered into several cell-line engineering collaborations including a commercial license agreement with Genenetech. The research phase of our co
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
2. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
3. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
4. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
5. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
6. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
7. Anaptys Biosciences Raises Over $33 Million in Series B Financing
8. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
9. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update
10. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
11. Regado Biosciences to Present at 19th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Aug. 22, 2014 (HealthDay News) -- Back-to-school time provides ... that fits into the family schedules, an expert suggests. ... child,s school year can also be the start of ... Richards, a professor of kinesiology at the University of ... release. With kids, extracurricular activities likely to build ...
(Date:8/22/2014)... 22, 2014 Dayton Children's Hospital broke ground ... part of a $141 million campus renewal. Renderings ... were unveiled to the public. , The new patient ... will create a campus that meets the needs of patients, ... care spaces will embody Dayton Children’s unique patient care mission ...
(Date:8/22/2014)... CLEVELAND Renal artery stenting to open blockages ... have historically been excluded from modern clinical trials, ... e-published in Catheterization and Cardiovascular Interventions ... Interventions (SCAI). , University Hospitals Case Medical Center,s ... and Professor of Medicine, Case Western Reserve University ...
(Date:8/22/2014)... Menstrual leaks risk stains and embarrassment, especially ... that there needed to be a better way to ... in design variations, the Safety Net optimizes protection during ... embarrassment and promotes peace of mind. The pad serves ... original design was submitted to the Fort Lauderdale office ...
(Date:8/22/2014)... who use reduced-nicotine cigarettes don,t smoke more to make ... a new study. This means they don,t inhale ... The month-long study included 72 adult smokers, aged ... emission levels of 1.2 milligrams (mg) each for one ... the next three weeks. In each of those ...
Breaking Medicine News(10 mins):Health News:With Kids in School, Parents Can Work Out 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 4Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 5Health News:UH Case Medical Center's Dr. Parikh authors SCAI paper on renal artery stenosis treatment 2Health News:UH Case Medical Center's Dr. Parikh authors SCAI paper on renal artery stenosis treatment 3Health News:Low-Nicotine Cigarettes May Not Lead to More Smoking 2
... response to the growing,demand for solutions to ... United,States, a group of entrepreneurs has established ... consulting,firm with over 25 years experience in ... implement pharmaceutical care, and,"Inspire Pharmacists to Practice ...
... Quantify Competitive Treatment Landscape and Support Model-Based Drug ... ... 27 Pharsight,Corporation (Nasdaq: PHST ), a leading provider of ... that it has licensed its public-source Type II,Diabetes meta- database to ...
... Oxygen Community Praises Congressman for Formally Opposing Deep,Cuts ... March 26 Pacific Pulmonary,Services - Ukiah Center, ... and services to more than 200 patients in ... Thompson (CA-1st) to,meet with patients, physicians and technicians ...
... Actuaries Unveil Election 2008 Resources for Voters on ... The American Academy of,Actuaries said the most ... address the program,s long-term financing issues.,According to the ... income from payroll taxes, and Medicare must,rely also ...
... in 2008, -- IND filing for liquid formulation NGX-1998 expected in first half of ... ... under EMEA review for neuropathic pain ... Calif., March 26 NeurogesX, Inc.,(Nasdaq: NGSX ), a biopharmaceutical company focused on developing ...
... Hillenbrand,Industries, Inc. (NYSE: HB ) (the "Company") announced ... in connection with its previously,announced cash tender offer to ... Notes due 2009 (CUSIP No. 431573AD6). The tender offer ... February 29, 2008 (the,"Offer to Purchase") and the related ...
Cached Medicine News:Health News:Tabula Rasa Strategies(TM), LLC, Announces Their Company Launch - A 'Clean Slate' Approach to the Practice of Pharmaceutical Care 2Health News:Tabula Rasa Strategies(TM), LLC, Announces Their Company Launch - A 'Clean Slate' Approach to the Practice of Pharmaceutical Care 3Health News:Pharsight Signs New Diabetes Meta-Database Customer 2Health News:Pharsight Signs New Diabetes Meta-Database Customer 3Health News:Ukiah Home Oxygen Therapy Patients and Physicians Meet with Congressman Mike Thompson to Share Benefits of Quality Home Oxygen Care 2Health News:Ukiah Home Oxygen Therapy Patients and Physicians Meet with Congressman Mike Thompson to Share Benefits of Quality Home Oxygen Care 3Health News:Medicare Trustees' Report Highlights Need for Reform 2Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 2Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 3Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 4Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 5Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 6Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 7Health News:NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results 8Health News:Hillenbrand Industries, Inc. Announces Pricing of Its Pending 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 2Health News:Hillenbrand Industries, Inc. Announces Pricing of Its Pending 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 3Health News:Hillenbrand Industries, Inc. Announces Pricing of Its Pending 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 4
(Date:8/22/2014)... , August 22, 2014 ... http://www.researchandmarkets.com/research/x34qgv/global_laboratory ) has announced the addition of ...  report to their offering.       ... an essential instrument for any modern science ... weighing of materials. It can be broadly ...
(Date:8/22/2014)... DUBLIN , August 22, 2014 /PRNewswire/ ... ) has announced the addition of the  ... to their offering.       (Logo: ... room with a sterile environment in a ... It is equipped with technically advanced equipment, ...
(Date:8/22/2014)... WASHINGTON , Aug. 22, 2014 ... Obamacare that modify the religious "accommodation" but still ... drugs that have an abortifacient effect, including Plan ... "week after pill"). The Obama Administration also announced ... religious, closely held, for-profit corporations. The ...
Breaking Medicine Technology:Global Laboratory Electronic Balance Market 2014-2018: Key Vendors are A&D Company, Mettler-Toledo, Sartorius and Thermo Fisher 2Global Operating Room Equipment Market 2014-2018: Key Vendors are Getinge, STERIS, Stykron and TRUMPF Medical Systems 2Liberty Institute: Government "Accommodation" Still Requires Employers To Facilitate Coverage Of Abortifacient Drugs 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: